| Literature DB >> 22534708 |
Nikolaos P E Kadoglou1, Ioannis S Vrabas, Alkistis Kapelouzou, Stilianos Lampropoulos, Nikolaos Sailer, Alkiviadis Kostakis, Christos D Liapis, Nikoletta Angelopoulou.
Abstract
BACKGROUND: Accumulating data support the atheroprotective role of the novel adipokines, apelin and ghrelin. The aim of the present randomized study was to investigate the effects of aerobic exercise training on these adipokines in patients with type 2 diabetes mellitus (T2DM). MATERIAL/Entities:
Mesh:
Substances:
Year: 2012 PMID: 22534708 PMCID: PMC3560628 DOI: 10.12659/msm.882734
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Baseline characteristics of participants who completed the study.
| Exercise group (n=26) | Control group (n=27) | p | |
|---|---|---|---|
| Gender (Men/Women) | 9/17 | 10/17 | 0.912 |
| Age (y) | 58.4±5.7 | 62.9±4.2 | 0.420 |
| Diabetes duration (y) | 5.1±2.5 | 5.5±2.1 | 0.787 |
| Smokers | 5 (19.2%) | 4 (14.8%) | 0.291 |
| Anti-hypertensive medications (n) | 16 (61.5%) | 19 (70.4%) | 0.333 |
| Statins (n) | 15 (57.69%) | 18 (66.67%) | 0.456 |
| Anti-diabetic regimen (n) | |||
| Sulfonylurea | 3 | 2 | 0.123 |
| Metformin | 5 | 7 | 0.243 |
| Sulfonylurea + metformin | 12 | 14 | 0502 |
| DPP4 inhibitors + metformin | 6 | 4 | 0.091 |
| Apelin (ng/ml) | 0.209±0.102 | 0.213±0.114 | 0.824 |
| Ghrelin (ng/ml) | 2.51±1.81 | 2.76±1.86 | 0.729 |
| HOMA-IR | 5.91±3.69 | 4.97±2.16 | 0.286 |
| Insulin (mU/L) | 9.38±4.82 | 8.93±4.11 | 0.370 |
Data are mean ±SD. n – number of patients; y – years; DPP4 – dipeptidyl-peptidase 4; HOMA-IR – homeostasis model assessment-insulin resistance.
Baseline and end-values of variables in both groups.
| Exercise group (n=26) | Control group (n=27) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | 12 weeks | P1 | Baseline | 12 weeks | P1 | P2 | |
| BMI (kg/m2) | 32.1±3.77 | 31.98±3.03 | 0.500 | 30.04±2.95 | 30.65±3.55 | 0.267 | 0.820 |
| WHR | 0.98±0.05 | 0.98±0.05 | 0.920 | 0.97±0.11 | 0.98±0.14 | 0.711 | 0.599 |
| Systolic BP (mmHg) | 137±15 | 128±16 | 0.016 | 135±15 | 136±19 | 0.714 | 0.017 |
| Diastolic BP (mmHg) | 82±11 | 80±10 | 0.085 | 81±11 | 81±10 | 0.879 | 0.163 |
| HbA1c (%) | 7.8±0.8 | 7.1±1 | <0.001 | 7.7±0.6 | 7.9±0.1.1 | 0.422 | 0.004 |
| FPG (mg/dl) | 191±40 | 162±41 | <0.001 | 188±36 | 194±33 | 0.656 | 0.008 |
| TChol (mg/dl) | 202±58 | 178±51 | 0.047 | 197±48 | 204±57 | 0.523 | 0.032 |
| HDL-C (mg/dl) | 42±11 | 47±10 | 0.007 | 44±11 | 43±10 | 0.417 | 0.018 |
| LDL-C (mg/dl) | 128±46 | 106±39 | 0.036 | 123±45 | 126±55 | 0.473 | 0.012 |
| TG (mg/dl) | 160±55 | 125±57 | 0.035 | 150±63 | 175±76 | 0.102 | 0.005 |
Data are mean ±SD. BMI – body mass index; WHR, – Waist-hip ratio; BP – blood pressure; FPG – Fasting plasma glucose; TChol – total cholesterol; TG – triglycerides. P1 – p values of changes of variables within groups; P2 – p values of changes of variables between groups.
Figure 1Values of apelin ghrelin VO2peak and HOMA-IR at baseline and at the end of the study. * p<0.05, change of variables within groups. # p<0.05, change of variables between groups. Data are mean ±SD.